Nothing said here yet.
to join the conversation.
| YERXA BENJAMIN RPresident | Sell | 25,520 | $90.1K | Fri, Oct 23 |
| Gagnon Robert E.Chief Financial Officer | Sell | 14,000 | $49.6K | Fri, Oct 23 |
| Magrath GeorgeChief Executive Officer | Sell | 9,591 | $34.4K | Fri, Oct 23 |
| YERXA BENJAMIN RPresident | Sell | 7,669 | $27.2K | Fri, Oct 23 |
| SCHACHLE JOSEPH KChief Operating Officer | Sell | 4,767 | $17.0K | Fri, Oct 23 |
| Foundation Fighting Blindness Retinal Degeneration FundDirector | Sell | 556,000 | $2.8M | Wed, Sep 30 |
| Gagnon Robert E.Chief Financial Officer | Sell | 28,000 | $127.2K | Thu, Sep 3 |
Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel featuring Chief Executive…
The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.
Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) are waiting on the same decision. By October 17, the FDA is due to rule on MR-141, an eye drop known as phentolamine 0.75%, as a treatment for presbyopia, the age-related loss of near focus.
Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.
Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1.
Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study
Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027.